Roberto Collu’s Post

The FNIH comparison of leading Alzheimer's blood tests has now been published. Tests were from C2N, Fujirebio, ALZPath, Janssen, Roche and Quanterix. Plasma measures of %p-tau217 and p-tau217 best predicted amyloid and tau PET, brain volumes, and dementia. Alzheimer's and Dementia allowed publication of an expanded paper to describe this rich dataset. All the code was provided to help investigators easily replicate and extend the findings. Data can be downloaded from http://adni.loni.usc.edu. #Alzheimer #AlzheimersResearch #FNIH #BridgestoBreakthroughs #BiomarkersConsortium #AmyloidPlaques #BloodTests #EarlyDiagnosis #Neuroscience

I’m thrilled to start the year off right by sharing our latest research on mitotherapy as a potential therapeutic strategy for chemotherapy-induced painful neuropathy. Oxaliplatin, a powerful antineoplastic agent, is unfortunately limited by painful peripheral neuropathy. Our findings suggest that mitotherapy could be a game-changer in pain management for patients undergoing oxaliplatin treatment. #Neuroscience #Research #PainManagement #Mitotherapy #OIPN #Oxaliplatin #NeuropathyRelief 🧠💊 Claudia Figueiredo Robson da Costa 📚 Read the Full Manuscript:

Our review is finally out in Nature Reviews Neuroscience! This article highlights the significance of cell type specific roles APOE, detailing major CNS cells for the implications of Alzheimer disease. We also discuss potential therapeutic approaches for targeting APOE and propose an APOE4 dependent hypothesis of AD pathogenesis. Writing this review has been one of the time-intensive and meticulous processes of my PhD so far. But I got to collaborate with two of the most amazing scientists and friends, Jessica Blumenfeld and Oscar Yip, I could have asked for! https://lnkd.in/dF92sw-9

It's incredibly gratifying to witness the realization of an idea I've been advocating for publicly over the years. The concept was to counteract the resistance to levodopa, a cost-effective treatment for the initial symptoms of Parkinson's disease, by introducing a skin patch or subcutaneous injection. This approach aimed to circumvent the inactivation of levodopa by gut microbes, presenting a strategic solution to a longstanding issue. The recent success of Neuroderm's positive phase 3 results, aligning with this very principle, marks a significant milestone in the field. #parkinson #neuroscience #neurology #neuroderm #Mitsubishitanabe

🚨 New Blog Post Alert! 🚨 Living with Multiple System Atrophy (MSA) is a challenging journey, but there's hope on the horizon. Discover one patient's inspiring experience with the Harvard Biomarkers Study and the MyTrial program at Khurana Labs. Learn how cutting-edge precision medicine is paving the way for targeted treatments and better outcomes. Join us as we delve into the incredible advancements in neurodegenerative disease research and the promise they hold for the future. Click the link below to read the full story! 🌟✨ 🔗 https://lnkd.in/gsCiEVMm #MultipleSystemAtrophy #PrecisionMedicine #HarvardBiomarkersStudy #MyTrialProgram #NeurodegenerativeDisease #MedicalResearch #HopeForACure #BrighamAndWomens #MassGeneral #HealthJourney #MedicalBreakthroughs #MSAawareness #FindPurpose #OvercomeFatigue #LoveBeyondMyself #EmbraceMemories #StrengthInUnity #Support #Empathy #Hope #LivingWithMSA #TerminalIllnessAwareness #MSAawareness #MedicalResearch #NeuroScience #NeurologicalDisorders #HealthAndWellness #NeurologicalDiseases #MSAAwareness #BeyondParkinsons #NeurologicalHealth #BrainHealth #OvercomingMSA #Unbreakable #StayingStrong #PositiveSpirit #HopeInAdversity #EarlyDetection #FamilySupport #NeurodegenerativeDiseases #MSAJourney #FuckMSA #TogetherStronger #MSAWarrior #MultipleSystemAtrophy #ChronicIllness #Perseverance #Resilience #NeverGiveUp #HopeForACure #EmbracingHope #ResilienceInAdversity #Parkinsonism

In recognition of #globalalzheimersmonth we wanted to share with you how non-invasive brain stimulation and imaging techniques like TMS and EEG can offer some valuable early indicators of efficacy to Phase 1 clinical trials for this indication. #clinicaltrials #neuroscience #alzheimers https://lnkd.in/eF_ZjvUf

🧠 How are you leveraging biomarkers like GFAP and p-Tau 231? Linked with conditions from Alzheimer’s to TBI, these markers offer insights into neurological research. Explore neurology biomarkers and their applications in research. #Neurology #Biomarkers

Recent research from Tianjin Medical University reveals that sigma-1 receptor (Sig-1R) agonists can protect against ferroptosis, a recently discovered type of neuronal death. This study, published in Brain Research, highlights the potential of Sig-1R agonists to enhance motor function recovery, reduce neuronal apoptosis, and inhibit inflammation and iron accumulation in Spinal Cord Injury (SCI) models by modulating the IRE1α pathway. The implications of these findings extend beyond SCI, offering new therapeutic strategies for a range of neurological disorders where ferroptosis plays a critical role. Specifically, in Fragile X Syndrome (FXS), caused by a mutation in the FMR1 gene leading to intellectual disabilities and synaptic dysfunction, modulating RNA-binding proteins related to FMRP, such as FXR1, can influence ferroptosis. Targeting Sig-1R could inhibit ferroptosis through the IRE1α pathway and provide neuroprotection, potentially altering the course of the disease. At Advantx Pharmaceuticals, we are committed to advancing the understanding of neurological diseases and developing innovative therapies. The findings from Tianjin Medical University General Hospital align with our mission to explore new treatment avenues, particularly those involving Sig-1R activation and its broad neuroprotective effects. #Ferroptosis #Sigma1Receptor #Neurology #FragileXSyndrome #Neuroprotection #SpinalCordInjury #Neuroscience #MedicalResearch #InnovativeTherapies #AdvantxPharmaceuticals #IRE1Alpha #Neuroinflammation #BiomedicalResearch https://lnkd.in/dkFRfHYJ

Excited to start my first NIH-funded Alzheimer’s disease (AD) project with my coPIs Drs. Ali Faridar and Juan Toledo (Dept of Neurology, Houston Methodist). This multi-PI, new R56 project will leverage our team’s expertise in molecular immunology in neurodegenerative disorders, biomarkers, genomics, neuropathology, neuroinflammation, single cell transcriptomics and multi-omics analyses. We will test our hypothesis that AD and frontotemporal disorder (FTD) have shared and unique immune responses that we can detect peripherally and identify the sources of these distinguishing immune response genes in the brain. The goal of this study is to discover novel drug targets to treat AD and FTD, which are devastating neurodegenerative diseases that affect brain function and are anticipated to affect a growing number of individuals as our life spans increase.#Alzheimersdiease, #neurodenegeration, #Houstonmethodist, #NIH, #singlecell, #CornellMed, #neuroinflammation

Study focus = “For TBI, the pathology evolves and changes over time, meaning that a single protein or receptor may be upregulated at one phase of the injury, but not two weeks later,” said Sarah Stabenfeldt. “This dynamic environment makes developing a successful targeting strategy complicated.” *Note: Two of those changes: BBB and mitochondria* (The blood-brain barrier (BBB) barrier is a barrier between the vascular and brain tissue. In a healthy individual, the BBB tightly regulates nutrient and waste exchange from the blood to the brain and vice versa, essentially compartmentalizing the brain/central nervous system.) (Mitochondria are the energy powerhouse of the cell) Findings = “It was really interesting to see that proteins involved in neurodegenerative diseases were detected at 7 days post-injury, but not at the earlier, 1-day post-injury time point." Initial injury = When a TBI occurs, the initial injury can disrupt the BBB, which triggers a cascade of cell death, torn, disrupted tissues and debris. Long-term injury= The long-term injury causes inflammation and swelling, and results in the immune response to spring into action, but also can lead to an impairment of the brain’s energy sources, or can choke off the brain’s blood supply, leading to more neuronal cell death and permanent disability. Result = It may also begin to explain why people who have had a TBI are more susceptible to developing neurodegenerative diseases like Parkinson’s and Alzheimer’s later in life. #CTE #brainhealth #neurology #BBB #mitochondria #neurofit